RGNX · Regenxbio Inc
United States · RS rating 26 · As of 2026-11-03
| Price | 7.63 USD |
|---|---|
| 1-day change | +6.6% |
| RS rating (overall / 1M / 3M / 12M) | 26 / 52 / 23 / 26 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 17 / 17 / 16 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -8.3% |
| Sales growth Q/Q | +2.0% |
| Distance from 52-week high | +52.2% |
| Market cap (USD) | $464.0M |